Dr. Gaggar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
303 Velocity Way
Foster City, CA 94404- Is this information wrong?
Education & Training
- University of California (San Francisco)Fellowship, Infectious Disease, 2008 - 2011
- University of California (San Francisco)Residency, Internal Medicine, 2006 - 2010
- University of Washington School of MedicineClass of 2006
Certifications & Licensure
- CA State Medical License 2008 - 2014
Clinical Trials
Publications & Presentations
PubMed
- Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.Janssen, H., Lim, Y., Kim, H., Sowah, L., Tseng, C., Coffin, C., Elkhashab, M., Ahn, S., Nguyen, A., Chen, D., Wallin, J., Fletcher, S., McDonald, C., Yang, J., Gaggar...> ;JHEP Reports. 2024 Feb 1
- 3 citationsIntrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells.Abhishek Aggarwal, Pamela M Odorizzi, Jens Brodbeck, Nicholas van Buuren, Christina Moon, Silvia Chang, MaryVic Adona, Silpa Suthram, Vithika Suri, Torsten Trowe, Scot...> ;JHEP Reports. 2023 Apr 1
- 8 citationsSafety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.Gane, E., Dunbar, P., Brooks, A., Zhang, F., Chen, D., Wallin, J., van Buuren, N., Arora, P., Fletcher, S., Tan, S., Yang, J., Tang, L., Gaggar, A., Kottilil, S.> ;Journal of Hepatology. 2023 Mar 1
- Join now to see all
Journal Articles
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19Robert L Gottlieb, Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Gregory Huhn, JAMA
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Join now to see all
Press Mentions
- Trial Finds Drug Safe and Effective in Treating Hep-C During PregnancyJuly 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: